Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02550743 · ClinicalTrials.gov registry record · Phase 1
BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study
A Phase 1 study, sponsored by howard safran.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT02550743 is a Phase 1 study that was terminated before completion, run by howard safran. The registered enrollment target is 7 participants.
The verdict
NCT02550743, a Phase 1 study, was terminated before completion, sponsored by howard safran.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The primary goal of this Brown University Oncology Research Group is to determine that a safe dose of BYL719 can be administered with capecitabine and radiation in patients with rectal cancer. Therefore, the threshold of success for this phase I study is to establish safety.
Interventions
- DRUG Capecitabine
- RADIATION Radiation
- DRUG BYL719
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-06-03 |
| Est. Completion | 2018-11-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02550743
The ClinicalTrials.gov registry entry for NCT02550743 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is howard safran, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Capecitabine is the first listed.
NCT02550743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02550743 about?
NCT02550743 is a clinical study titled "BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study". The primary goal of this Brown University Oncology Research Group is to determine that a safe dose of BYL719 can be administered with capecitabine and radiation in patients with rectal cancer. Therefore, the threshold of success for this phase I study is to establish safety.
What is the current status of trial NCT02550743?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2016-06-03. Estimated completion is 2018-11-16.
What interventions are being tested in trial NCT02550743?
The interventions under investigation include: Capecitabine (DRUG), Radiation (RADIATION), BYL719 (DRUG).
Who is sponsoring clinical trial NCT02550743?
This trial is sponsored by howard safran, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.